Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4

Diabetes, Obesity and Metabolism

Volumn 18, Issue 11, 2016, Pages 1072-1080

  Blevins, T ^a   Pieber, T R ^b   Colon Vega G ^c   Zhang, S ^d   Bastyr, E J ^d,e   Chang, A M ^d  

^a Texas Diabetes and Endocrinology   (United States)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c American Telemedicine Center   (Puerto Rico)

^d ELI LILLY AND COMPANY   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

basal insulin; glycaemic control; hypoglycaemia; randomized trial; type 2 diabetes

Indexed keywords

AMINOTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; INSULIN ANTIBODY; INSULIN GLARGINE; INSULIN LISPRO; INSULIN PEGLISPRO; TRIACYLGLYCEROL; BASAL INSULIN PEGLISPRO; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; MACROGOL DERIVATIVE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; AGED; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; MEAL; METABOLISM; MIDDLE AGED;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN GLARGINE; INSULIN LISPRO; MALE; MEALS; MIDDLE AGED; POLYETHYLENE GLYCOLS;

EID: 84990211837     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12696     Document Type: Article

References (36)

1. Halban PA, Polonsky KS, Bowden DW et al. Beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care 2014; 37: 1751–1758.
2. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249–1258.
3. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140–149.
4. UK Prospective Diabetes Study (UKPDS) Group, Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005–2012.
5. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–1589.
6. Shah VN, Moser EG, Blau A, Dhingra M, Garg SK. The future of basal insulin. Diabetes Technol Ther 2013; 15: 727–732.
7. Ratner RE, Gough SC, Mathieu C et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013; 15: 175–184.
8. Ritzel R, Roussel R, Bolli GB et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab 2015; 17: 859–867.
9. Hansen RJ, Cutler GB, Vick A et al. LY2605541: leveraging hydrodynamic size to develop a novel basal insulin. Diabetes 2012; 61(Suppl. 1): A228.
10. Sinha VP, Choi SL, Soon DK et al. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. J Clin Pharmacol 2014; 54: 792–799.
11. Sinha VP, Howey DC, Choi SL, Mace KF, Heise T. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014; 16: 344–350.
12. Mudaliar S, Henry RR, Ciaraldi TP et al. Basal insulin peglispro (BIL) demonstrates hepato-preferential action vs. Insulin glargine (GL) in patients with type 1 diabetes mellitus (T1DM). Diabetes 2015; 64(Suppl. 1A): LB22–LB23.
13. Henry RR, Mudaliar S, Ciaraldi TP et al. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects. Diabetes Care 2014; 37: 2609–2615.
14. Morrow LA, Hompesch M, Jacober SJ, Choi SL, Qu Y, Sinha VP. Glucodynamics of long-acting basal insulin peglispro (BIL) compared with insulin glargine at steady state in subjects with type 1 diabetes: substudy of a randomized crossover trial. Diabetes Obes Metab 2016; May 12 [Epub ahead of print] doi:10.1111/dom.12691.
15. Moore MC, Smith MS, Sinha VP et al. Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes 2014; 63: 494–504.
16. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539–553.
17. Rosenstock J, Bergenstal RM, Blevins TC et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care 2013; 36: 522–528.
18. Bastyr EJ III, Zhang S, Mou J et al. Performance of an electronic diary system for intensive insulin management in Global Diabetes Clinical Trials. Diabetes Technol Ther 2015; 17: 571–579.
19. Dmitrienko A, Tamhane AC, Wiens BL. General multistage gatekeeping procedures. Biom J 2008; 50: 667–677.
20. Qu Y, Luo J. Estimation of group means when adjusting for covariates in generalized linear models. Pharm Stat 2015; 14: 56–62.
21. Davies MJ, Russel-Jones D, Selam J-L et al. Basal insulin peglispro vs insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial. Diabetes Obes Metab 2016 [Submitted Paper].
22. Grunberger G, Chen L, Rodríguez Á et al. A Randomized Clinical Trial of Basal Insulin Peglispro versus NPH in Insulin-Naïve Patients with Type 2 Diabetes: IMAGINE 6. Diabetes Obes Metab 2016 [Submitted Paper].
23. Garg SK, Dreyer M, Jinnouchi H et al. A Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in combination with Prandial insulin Lispro, in Patients with Type 1 Diabetes: IMAGINE 1. Diabetes Obes Metab 2016 [Submitted Paper].
24. Buse JB, Rodbard HW, Trescoli Serrano C et al. Randomized clinical trial comparing basal insulin peglispro and insulin glargine in patients with Type 2 diabetes previously treated with basal insulin: IMAGINE 5. Diabetes Care 2016; 39: 92–100.
25. Bergenstal RM, Lunt H, Franek E et al. A randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3. Diabetes Obes Metab 2016 doi: 10.1111/dom.12698.
26. Bergenstal RM, Rosenstock J, Arakaki RF et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012; 35: 2140–2147.
27. Ginsberg H, Cariou B, Orchard T et al. Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in 6 IMAGINE trials. Diabetes Obes Metab 2016 [Submitted Paper].
28. Chaudhuri A, Rosenstock J, DiGenio A et al. Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. Diabetes Metab Res Rev 2012; 28: 258–267.
29. Gerstein HC, Yale JF, Harris SB et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) study. Diabet Med 2006; 23: 736–742.
30. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49: 442–451.
31. Hoogwerf BJ, Lincoff AM, Rodriguez A et al. Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis. Cardiovasc Diabetol 2016; 15: 78.
32. Donnelly KL, Smith CI, Schwarzenberg SJ et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343–1351.
33. Vatner DF, Majumdar SK, Kumashiro N et al. Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids. Proc Natl Acad Sci 2015; 112: 1143–1148.
34. Mashhood A, Railkar R, Yokoo T et al. Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging. J Magn Reson Imaging 2013; 37: 1359–1370.
35. Juurinen L, Tiikkainen M, Hakkinen AM, Hakkarainen A, Yki-Jarvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292: E829–E835.
36. Lingvay I, Raskin P, Szczepaniak LS. Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complications 2007; 21: 137–142.